Chronic hepatitis from a psychiatric point of view;Psikiyatrik bakiş açisiyla kronik hepatitler

Anadolu Psikiyatri Dergisi

Volumn 9, Issue 4, 2008, Pages 253-260

  Özdemir, Samuray ^a   Yalug, Irem ^b   Mert, Ali ^c   Aker, Tamer ^b  

^a Kiziltepe Devlet Hastanesi   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Anxiety; Chronic hepatitis; Depression; Interferon

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ALCOHOLISM; CHRONIC HEPATITIS; COMORBIDITY; CONSULTATION; DEPRESSION; DISEASE COURSE; HEPATITIS B; HEPATITIS C; HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PSYCHIATRIST; REVIEW; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SYMPTOM; TEAMWORK;

EID: 65349117146     PISSN: 13026631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. WHO. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/ en
2. von DM, Verma A, Dougherty KA, Batey B, Russo M, Zacks S, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52:3251-3258.
3. El-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123:476-482.
4. Ozkan M, Corapcioglu A, Balcioglu I, Ertekin E, Khan S, Ozdemir S, et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med 2006; 36:283-297.
5. Batista-Neves, Quarantini LC, de Almeida AG, Bressan RA, Lacerda AL, de-Oliveira IR et al. High frequency of unrecognized mental disorders in HCV-infected patients. Gen Hosp Psychiatry 2008; 30:80-82.
6. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27:431-438.
7. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002; 36:401-407.
8. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-292.
9. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38:530-534.
10. Tuǧlu C, Kara SH, Çaliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacol (Berl) 2003; 170:429-433.
11. Simen B, Duman C, Simen A, Duman R. TNFα signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59:775-785.
12. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006; 60:77-79.
13. Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999; 461:117-127.
14. Loftis JM, Huckans M, Ruimy S, Hinrichs DJ, Hauser P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 2008; 430:264-268.
15. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26:112-121.
16. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-a therapy. Semin Oncol 1998; 25(Suppl. 1):39-47.
17. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157:683-694.
18. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001; 15:7-24.
19. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, et al. Illness, cytokines, and depression. Ann NY Acad Sci 2000; 917:478-487.
20. Yamano M, Yuki H, Yasuda S, Miyata K. Corticotropin-releasing hormone1 receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther 2000; 292:181-187.
21. Song C. The interaction between cytokines and neurotransmitters in depression and stress: possible mechanism of antidepressant treatments. Hum Psychopharmacol Clin Exp 2000; 15:199-211.
22. Vignau J, Karila L, Costisella O, Canva V. Hepatitis C, interferon and depression: main physiopathologic hypothesis. Encephale 2005; 31:349-357.
23. Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, et al. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int 2008; 28:477-485.
24. Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19:23-27.
25. Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005; 10:332-333.
26. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82:175-190.
27. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66:41-48.
28. Zdilar D, Franco-Bronson K, Buchler N, Locala J, Younossi Z. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31:1207-1211.
29. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
30. Lim JK, Cronkite R, Goldstein MK, Cheung RC. The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. J Clin Gastroenterol 2006; 40:528-534.
31. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76:600-608.
32. Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003; 10:81-86.
33. Ferenci P, Staufer K. Depression in chronic hepatitis: the virus, the drug, or the ethnic background? Liver Int 2008; 28:429-431.
34. Yumru M, Sirmatel F, Virit O, Savaş E, Savaş HA, Herken H. Interferon tedavisi alan ve almayan hepatit c hastalarinda anksiyete ve depresyon düzeyleri. Klinik Psikofarmakoloji Bülteni 2006; 16:155-159.
35. Centers for Disease Control Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47:1-39. http://www.cdc.gov/mmwr/ preview/mmwrhtml/00055154.htm
36. Rowan PJ, Dunn NJ, El-Serag HB, Kunik ME. Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. J Viral Hepat 2007; 14:883-889.
37. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004; 26:237-240.
38. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36:242-252.
39. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatric Pract 2003; 9:93-110.
40. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19:105-123.
41. Pariante CM, Orrù MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354:131-132.
42. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005; 42:793-798.
43. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997; 54:531-533.
44. Bini EJ. Singin' the blues: the downside of hepatitis C virus treatment. Am J Gastroenterol 2007; 102:2434-2436.
45. Schäfer M, Schmidt F, Amann B, Schlösser S, Loeschke K, Grunze H. Adding low dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. Neuropsychobiology 2000; 42:43-45.